<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736265</url>
  </required_header>
  <id_info>
    <org_study_id>2017ZX10203202003</org_study_id>
    <nct_id>NCT03736265</nct_id>
  </id_info>
  <brief_title>Carvedilol for Prevention of Esophageal Varices Progression</brief_title>
  <acronym>Carvedilol</acronym>
  <official_title>Clinical Study of Carvedilol for the Prevention of the Progression of Esophageal Varices in Hepatitis B Related Cirrhotic Patients With Anti-Viral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol.
      But the efficacy of carvedilol to delay the growth of esophageal varices in chronic hepatitis
      B patients was unclear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been concluded 40%-70% of chronic hepatitis B patients can achieve fibrosis/ cirrhosis
      reversion after effective anti-viral therapy. But there is still some patients progress to
      decompensation. Esophageal varices are the main complication of cirrhotic patients.
      Propranolol are widely used to prevent variceal bleeding in patients with large esophageal
      varices. It has been shown the efficacy of propranolol in the preventing of the progression
      from small to large varices reported no effect. Recently, carvedilol has been shown to be
      more potent in decreasing portal hypertension to propranolol. But the efficacy of carvedilol
      to delay the growth of esophageal varices in chronic hepatitis B patients was unclear. The
      purpose of this study is to demonstrate the efficacy of carvedilol in the preventing of the
      progression from small to large varices in hepatitis B patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The progression Incidence of esophageal varices.</measure>
    <time_frame>2 years</time_frame>
    <description>Progression of esophageal varices defines as follows:
Varices developed from small(F1) to medium or large(F2/F3)
Varices developed from medium(F2) to large(F3)
Bleeding from esophageal varices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of liver cirrhosis decompensation</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative rate of liver decompensation (including ascites,hepatic encephalopathy) after 2 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hepatic cellular carcinoma, death or liver transplantation.</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative rate of hepatic cellular carcinoma, death or liver transplantation after 2 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The progression rate of non-invasive scores (Child-Pugh、MELD、APRI、FIB-4 score).</measure>
    <time_frame>2 years</time_frame>
    <description>The progression rate of Child-Pugh、MELD、APRI、FIB-4 score after 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dynamic change of liver stiffness quantified by transient elastography.</measure>
    <time_frame>2 years</time_frame>
    <description>The dynamic change of liver stiffness quantified by transient elastography after 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dynamic change of hemodynamics parameter</measure>
    <time_frame>2 years</time_frame>
    <description>The dynamic change of hemodynamics (HR and mean arterial pressure) after 2 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Carvedilol+ Nucleos(t)ide Analogues</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nucleos(t)ide Analogues</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continuing take nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55/min.</description>
    <arm_group_label>Carvedilol+ Nucleos(t)ide Analogues</arm_group_label>
    <other_name>Nucleos(t)ide Analogues</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female;

          -  HBV-related liver cirrhotic patients with at least two years of antiviral therapy;

          -  The presence of small or medium esophageal varices without red color sign;

          -  HBV-DNA＜1×10E3 IU/ml

          -  Signature of informed consent

        Exclusion Criteria:

          -  Previous presence of decompensated cirrhosis including ascites, bleeding and HE
             (hepatic encephalopathy);

          -  Any contra-indications to beta-blockers including asthma, chronic obstructive
             pulmonary disease, allergic rhinitis, NYHA (New York Heart Association) class IV heart
             failure, atrioventricular block, sinus bradycardia (HR &lt; 50 / min), cardiogenic shock,
             hypotension (SBP &lt; 90 mmHg), sick sinus syndrome, insulin dependent diabetes,
             peripheral vascular disease.

          -  Allergic to Carvedilol;

          -  Any malignancy that affects survival；

          -  Renal dysfunction；

          -  History of beta-blockers within last 3 months；

          -  History of surgery for portal hypertension；History of prior EVL (endoscopic variceal
             ligation) or sclerotherapy, history of surgery for portal hypertension including
             portosystemic shunts, disconnection and spleen resection and transjugular intrahepatic
             portosystemic shunt；

          -  Severe systemic diseases；

          -  Refusal to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojuan Ou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoning Wu</last_name>
    <phone>+86-63138665</phone>
    <email>zdzxyyyy@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Ditan Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Xie</last_name>
      <email>Xiewen6218@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyuan Xu</last_name>
      <email>yangpin@public3.bta.net.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Feng</last_name>
      <email>xyfyfb_1@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoning Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Jiang</last_name>
      <email>jiang.wei@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingyi Xu</last_name>
      <email>xumingyi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojuan Ou</investigator_full_name>
    <investigator_title>Director of liver research center</investigator_title>
  </responsible_party>
  <keyword>Portal Hypertension</keyword>
  <keyword>Esophageal varices</keyword>
  <keyword>Carvedilol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

